Patents by Inventor Youhei Satou
Youhei Satou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151050Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: November 8, 2022Publication date: May 18, 2023Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20220162604Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: ApplicationFiled: June 30, 2021Publication date: May 26, 2022Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210340171Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: July 14, 2021Publication date: November 4, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210284680Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: May 28, 2021Publication date: September 16, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210261963Abstract: The present invention relates to a composition containing an antisense oligonucleotide, and the use thereof to treat Duchenne muscular dystrophy. The present invention particularly relates to the above-described composition that is effective for the treatment of Duchenne muscular dystrophy when it is administered at a dose for the treatment, and the use thereof.Type: ApplicationFiled: June 26, 2019Publication date: August 26, 2021Applicant: NIPPON SHINYAKU CO., LTD.Inventors: Tomonori UNO, Takashi NATSUKAWA, Youichi EGAWA, Youhei SATOU
-
Patent number: 11053497Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: GrantFiled: June 11, 2019Date of Patent: July 6, 2021Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20210198306Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: February 12, 2021Publication date: July 1, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20210179659Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: December 18, 2020Publication date: June 17, 2021Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 11028122Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: February 12, 2021Date of Patent: June 8, 2021Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 10870676Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: May 10, 2019Date of Patent: December 22, 2020Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 10683322Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: December 17, 2019Date of Patent: June 16, 2020Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Patent number: 10662217Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: December 12, 2019Date of Patent: May 26, 2020Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20200149040Abstract: Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.Type: ApplicationFiled: June 11, 2019Publication date: May 14, 2020Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 10647741Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: June 24, 2019Date of Patent: May 12, 2020Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20200115411Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: May 10, 2019Publication date: April 16, 2020Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20200109162Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: December 17, 2019Publication date: April 9, 2020Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Publication number: 20200102343Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: December 12, 2019Publication date: April 2, 2020Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 10487106Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: March 29, 2019Date of Patent: November 26, 2019Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
-
Publication number: 20190315796Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: ApplicationFiled: June 24, 2019Publication date: October 17, 2019Applicants: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
-
Patent number: 10407461Abstract: The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.Type: GrantFiled: March 26, 2019Date of Patent: September 10, 2019Assignees: NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata